RT Journal Article
SR Electronic
T1 Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.16.22276480
DO 10.1101/2022.06.16.22276480
A1 Chansaenroj, Jira
A1 Suntronwong, Nungruthai
A1 Kanokudom, Sitthichai
A1 Assawakosri, Suvichada
A1 Yorsaeng, Ritthideach
A1 Vichaiwattana, Preeyaporn
A1 Klinfueng, Sirapa
A1 Wongsrisang, Lakana
A1 Srimuan, Donchida
A1 Thatsanatorn, Thaksaporn
A1 Thongmee, Thanunrat
A1 Auphimai, Chompoonut
A1 Nilyanimit, Pornjarim
A1 Wanlapakorn, Nasamon
A1 Sudhinaraset, Natthinee
A1 Poovorawan, Yong
YR 2022
UL http://medrxiv.org/content/early/2022/06/17/2022.06.16.22276480.abstract
AB Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccinated with two doses of BBIBP-CorV vaccine and to explore the boosting effect of the different vaccine platforms in BBIBP-CorV-primed healthy adults, including viral vector vaccine (AZD122) and mRNA vaccines (BNT162b2 and mRNA-1273). The results showed that, in the BBIBP-CorV prime group, the total receptor-binding domain (RBD) immuno-globulin (Ig) and anti-RBD IgG levels waned significantly at 3 months after receiving the second dose. However, after the booster, RBD-specific binding antibody levels increased. Neutralizing antibody measured by a surrogate neutralization test showed of inhibition over 90% against the SARS-CoV-2 delta variant but less than 70% against omicron variant after the third dose on day 28. All booster vaccines could induce the total IFN-□ T-cell response. The reactogenicity was acceptable and well tolerated without serious adverse events. This study supported administration of the third dose with either viral vector or mRNA vaccine for the BBIBP-CorV-primed individuals to stimulate antibody and T cell responses.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20211120002Funding StatementThis research was funded by a Health Systems Research Institute (HSRI), the National Research Council of Thailand (NRCT), the Center of Excellence in Clinical Virology of Chulalongkorn University/King Chulalongkorn Memorial Hospital (GCE 59-009-30-005), the Second Century Fund (C2F), Chulalongkorn University to Jira Chansaenroj and MK Restaurant Group Public CompanyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB numbers 871/64)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript